Orion, Shilpa Medicare Nivolumab Biosimilar Europe
Analysis based on 13 articles · First reported Jun 30, 2026 · Last updated Jul 06, 2026
The agreement between Orion and United States — Medicare for the nivolumab biosimilar in Europe is expected to positively impact the pharmaceutical market by increasing access to affordable cancer treatments. This collaboration could lead to increased revenue for both Orion and United States — Medicare, particularly as the originator nivolumab loses exclusivity, potentially easing pressure on healthcare budgets in Europe.
Orion and Shilpa Medicare — Shilpa Biologicals Private Limited, a subsidiary of United States — Medicare, have entered into an agreement to commercialize an intravenous nivolumab biosimilar in Europe. Under the terms, Shilpa Biologicals will develop and supply the biosimilar, while Orion gains exclusive rights to distribute, market, and sell it across Europe. Shilpa Biologicals will receive development and regulatory milestone payments, along with supply revenue. This partnership aims to expand Orion's presence in the European hospital segment and provide affordable cancer medicines, leveraging Shilpa Biologicals' manufacturing capabilities and Orion's commercial expertise. The nivolumab market in Europe was valued at approximately USD 4.1 billion in 2025.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard